Beta Bionics Announces $150M Public Offering of Common Stock

What Happened
Beta Bionics, Inc. announced on September 15, 2026 that it entered an underwriting agreement to sell 7,652,175 shares of common stock (and pre-funded warrants for 1,043,484 shares) at $17.25 per share, with gross proceeds expected to be approximately $150.0 million before underwriting discounts, commissions and expenses. The offering is led by J.P. Morgan, Piper Sandler, Wells Fargo Securities and Leerink Partners, and the closing is expected to occur on September 17, 2026, subject to customary closing conditions.

Key Details

• Offering size: 7,652,175 shares of common stock; plus pre-funded warrants to purchase 1,043,484 shares (pre-funded warrant purchase price $17.2499 each; $0.0001 exercise price).
• Public offering price: $17.25 per share. Gross proceeds expected to be ~ $150.0 million (before fees).
• Overallotment option: Underwriters have a 30-day option to buy up to 1,304,348 additional shares at the public offering price (less underwriting discounts/commissions).
• Use of proceeds: general corporate purposes, including commercialization of Mint™, manufacturing expansion, R&D and clinical development, product enhancements, potential strategic opportunities, and working capital.

Why It Matters
The financing, if completed, would materially increase Beta Bionics’ cash resources to support commercialization of its Mint™ product and related business activities. The offering dilutes existing shareholders but provides capital intended to fund growth, manufacturing scale-up and continued development. The closing remains subject to customary conditions and market factors; the company’s filing includes standard forward-looking statement cautioning that actual results may differ.